Cargando…
Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT
In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). A total of 30 patient...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979788/ https://www.ncbi.nlm.nih.gov/pubmed/27495034 http://dx.doi.org/10.1097/MD.0000000000004308 |
_version_ | 1782447375291252736 |
---|---|
author | Farnebo, Jacob Wadelius, Agnes Sandström, Per Nilsson, Sten Jacobsson, Hans Blomqvist, Lennart Ullén, Anders |
author_facet | Farnebo, Jacob Wadelius, Agnes Sandström, Per Nilsson, Sten Jacobsson, Hans Blomqvist, Lennart Ullén, Anders |
author_sort | Farnebo, Jacob |
collection | PubMed |
description | In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). A total of 30 patients with mCRPC were monitored with C11-acetate PET/CT and PSA levels during their treatment with AA. Retrospective evaluation of their response was made after 102 days (median; range 70–155) of treatment. Statistical analyses were employed to detect predictors of progression-free survival (PFS) and overall survival (OS), and potential correlation between serum levels of PSA, standardized uptake values (SUVpeak), and bone lesion index measured from PET were investigated. At follow-up 10 patients exhibited partial response (PR), 10 progressive disease (PD), and 10 stable disease (SD), as assessed by PET/CT. In survival analysis, both PR and PD were significantly associated with PFS and OS. CT response was also associated with OS, but only 19/30 patients demonstrated a lesion meeting target lesion criteria according to RECIST 1.1. No PET/CT baseline characteristic was significantly associated with PFS or OS. A PSA response (reduction in the level by >50%) could also predict PFS and OS. In the subgroup lacking a PSA response, those with PD had significantly shorter OS than those with PR or SD. PFS and OS in patients with mCRPC treated with AA can be predicted from repeated C11-acetate PET/CT. This may be of particular clinical value in patients who do not exhibit a PSA response to treatment. |
format | Online Article Text |
id | pubmed-4979788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-49797882016-08-18 Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT Farnebo, Jacob Wadelius, Agnes Sandström, Per Nilsson, Sten Jacobsson, Hans Blomqvist, Lennart Ullén, Anders Medicine (Baltimore) 5700 In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). A total of 30 patients with mCRPC were monitored with C11-acetate PET/CT and PSA levels during their treatment with AA. Retrospective evaluation of their response was made after 102 days (median; range 70–155) of treatment. Statistical analyses were employed to detect predictors of progression-free survival (PFS) and overall survival (OS), and potential correlation between serum levels of PSA, standardized uptake values (SUVpeak), and bone lesion index measured from PET were investigated. At follow-up 10 patients exhibited partial response (PR), 10 progressive disease (PD), and 10 stable disease (SD), as assessed by PET/CT. In survival analysis, both PR and PD were significantly associated with PFS and OS. CT response was also associated with OS, but only 19/30 patients demonstrated a lesion meeting target lesion criteria according to RECIST 1.1. No PET/CT baseline characteristic was significantly associated with PFS or OS. A PSA response (reduction in the level by >50%) could also predict PFS and OS. In the subgroup lacking a PSA response, those with PD had significantly shorter OS than those with PR or SD. PFS and OS in patients with mCRPC treated with AA can be predicted from repeated C11-acetate PET/CT. This may be of particular clinical value in patients who do not exhibit a PSA response to treatment. Wolters Kluwer Health 2016-08-07 /pmc/articles/PMC4979788/ /pubmed/27495034 http://dx.doi.org/10.1097/MD.0000000000004308 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5700 Farnebo, Jacob Wadelius, Agnes Sandström, Per Nilsson, Sten Jacobsson, Hans Blomqvist, Lennart Ullén, Anders Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT |
title | Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT |
title_full | Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT |
title_fullStr | Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT |
title_full_unstemmed | Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT |
title_short | Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT |
title_sort | progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial c11-acetate pet/ct |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979788/ https://www.ncbi.nlm.nih.gov/pubmed/27495034 http://dx.doi.org/10.1097/MD.0000000000004308 |
work_keys_str_mv | AT farnebojacob progressionfreeandoverallsurvivalinmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetatecanbepredictedwithserialc11acetatepetct AT wadeliusagnes progressionfreeandoverallsurvivalinmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetatecanbepredictedwithserialc11acetatepetct AT sandstromper progressionfreeandoverallsurvivalinmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetatecanbepredictedwithserialc11acetatepetct AT nilssonsten progressionfreeandoverallsurvivalinmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetatecanbepredictedwithserialc11acetatepetct AT jacobssonhans progressionfreeandoverallsurvivalinmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetatecanbepredictedwithserialc11acetatepetct AT blomqvistlennart progressionfreeandoverallsurvivalinmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetatecanbepredictedwithserialc11acetatepetct AT ullenanders progressionfreeandoverallsurvivalinmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetatecanbepredictedwithserialc11acetatepetct |